Literature DB >> 26959123

Drug Delivery Nanoparticles: Toxicity Comparison in Retinal Pigment Epithelium and Retinal Vascular Endothelial Cells.

Haijiang Lin1, Yueran Yue1, Daniel E Maidana1, Peggy Bouzika1, Alp Atik1, Hidetaka Matsumoto1, Joan W Miller1, Demetrios G Vavvas1.   

Abstract

Multiple synthetic polymer nanoparticles (NPs) have been widely used as drug delivery systems. However, their toxicity to the retinal pigment epithelium and retinal endothelium remains unclear. In this study, we analyze the cytotoxic effects of three different kinds of NPs, made of poly lactic-co-glycolic acid (PLGA), polycaprolactone (PCL), and PEGylated PLGA (PEG-PLGA), in a retinal pigment epithelium cell line (ARPE-19) and in primary human retinal vascular endothelial cells (RVEC). PEG-PLGA NPs presented the lowest cytotoxicity on ARPE-19 cells and RVEC as assessed by MTT viability assay. While PLGA and PCL exhibited variable amounts of toxicity, no significant toxicity was observed when incubating cells with high PEG-PLGA concentrations (100 µg/ml), for up to 6 days. On both transmission electron microscopy and confocal microscopy, Rhodamine 6G-loaded PEG-PLGA NPs were observed intracellularly in multiple subcellular organelles. PEG-PLGA NPs are a potentially viable option for the treatment of eye diseases.

Entities:  

Keywords:  Cellular uptake; PEG-PLGA; nanoparticle; pegylation; retina; subcellular localization

Mesh:

Substances:

Year:  2016        PMID: 26959123      PMCID: PMC5405708          DOI: 10.3109/08820538.2015.1114865

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  27 in total

Review 1.  Introduction and overview of peptide and protein pegylation.

Authors:  Francesco M Veronese; J Milton Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

2.  Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study.

Authors:  Aaron C Eifler; C Shad Thaxton
Journal:  Methods Mol Biol       Date:  2011

3.  Internalization and subcellular fate of aptamer and peptide dual-functioned nanoparticles.

Authors:  Huile Gao; Zhi Yang; Shuang Zhang; Zhiqing Pang; Xinguo Jiang
Journal:  J Drug Target       Date:  2014-02-11       Impact factor: 5.121

4.  Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment.

Authors:  Reyhaneh Varshochian; Mohammad Riazi-Esfahani; Mahmood Jeddi-Tehrani; Ahmad-Reza Mahmoudi; Sara Aghazadeh; Mirgholamreza Mahbod; Morteza Movassat; Fatemeh Atyabi; Araz Sabzevari; Rassoul Dinarvand
Journal:  J Biomed Mater Res A       Date:  2015-03-27       Impact factor: 4.396

5.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08

6.  The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress.

Authors:  Wei Wang; Wei Xiong; Jiangling Wan; Xiaohui Sun; Huibi Xu; Xiangliang Yang
Journal:  Nanotechnology       Date:  2009-02-16       Impact factor: 3.874

7.  Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV.

Authors:  S R Singh; H E Grossniklaus; S J Kang; H F Edelhauser; B K Ambati; U B Kompella
Journal:  Gene Ther       Date:  2009-02-05       Impact factor: 5.250

8.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

9.  Effect of polyethylene glycol modification of TiO₂nanoparticles on cytotoxicity and gene expressions in human cell lines.

Authors:  Sharmy Saimon Mano; Koki Kanehira; Shuji Sonezaki; Akiyoshi Taniguchi
Journal:  Int J Mol Sci       Date:  2012-03-21       Impact factor: 6.208

10.  Unambiguous observation of shape effects on cellular fate of nanoparticles.

Authors:  Zhiqin Chu; Silu Zhang; Bokai Zhang; Chunyuan Zhang; Chia-Yi Fang; Ivan Rehor; Petr Cigler; Huan-Cheng Chang; Ge Lin; Renbao Liu; Quan Li
Journal:  Sci Rep       Date:  2014-03-28       Impact factor: 4.379

View more
  4 in total

1.  Combination of cGMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration.

Authors:  Eleonora Vighi; Dragana Trifunović; Patricia Veiga-Crespo; Andreas Rentsch; Dorit Hoffmann; Ayse Sahaboglu; Torsten Strasser; Manoj Kulkarni; Evelina Bertolotti; Angelique van den Heuvel; Tobias Peters; Arie Reijerkerk; Thomas Euler; Marius Ueffing; Frank Schwede; Hans-Gottfried Genieser; Pieter Gaillard; Valeria Marigo; Per Ekström; François Paquet-Durand
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-12       Impact factor: 11.205

2.  Time-Dependent Internalization of Polymer-Coated Silica Nanoparticles in Brain Endothelial Cells and Morphological and Functional Effects on the Blood-Brain Barrier.

Authors:  Aniela Bittner; Fabien Gosselet; Emmanuel Sevin; Lucie Dehouck; Angélique D Ducray; Véronique Gaschen; Michael H Stoffel; Hansang Cho; Meike Mevissen
Journal:  Int J Mol Sci       Date:  2021-02-06       Impact factor: 5.923

3.  Unconjugated PLGA nanoparticles attenuate temperature-dependent β-amyloid aggregation and protect neurons against toxicity: implications for Alzheimer's disease pathology.

Authors:  Pallabi Sil Paul; Jae-Young Cho; Qi Wu; Govindarajan Karthivashan; Emily Grabovac; Holger Wille; Marianna Kulka; Satyabrata Kar
Journal:  J Nanobiotechnology       Date:  2022-02-04       Impact factor: 10.435

Review 4.  Nanoparticles in ocular applications and their potential toxicity.

Authors:  Cao Yang; Junling Yang; Ao Lu; Jing Gong; Yuanxing Yang; Xi Lin; Minghui Li; Haiwei Xu
Journal:  Front Mol Biosci       Date:  2022-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.